Alimentiv Inc., AcelaBio Inc. and PharmaNest Inc. announce a collaboration to provide precision medicine and artificial intelligence (AI)-powered digital pathology solutions for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). This collaboration will enable clinical trial sponsors to quantify the histological effects of drugs and gain deeper insights into the underlying mechanisms in MASH-targeted therapies using state-of-the-art spatial transcriptomics and AI-powered digital pathology for individual fibers and cells . The collaboration brings together the collective expertise of Alimentiv, AcelaBio and PharmaNest, creating an integrated ecosystem that seamlessly connects high-throughput anatomical and molecular pathology, precision medicine technologies, bioinformatics and AI-powered digital pathology image analysis. The integration of these cutting-edge solutions represents a significant advance in the application of novel technologies that enable high-quality, end-to-end tissue analysis and enable clinical trial sponsors to advance scientific discoveries and accelerate drug development for MASH – a Disease with growing effects for which there is currently no approved treatment.
AcelaBio, a CAP/CLIA-certified clinical research laboratory known for its holistic digital pathology workflows, will analyze tissue samples to produce full slide images and molecular data. “Our collaboration holds great potential for the further development of clinical MASH research. It enables the identification and quantification of digital pathology biomarker data and improves clinical development,” said Dr. Niels Vande Casteele , President of AcelaBio. “By creating seamless workflows that integrate advanced sample analysis, digital pathology, bioinformatics and AI-powered analysis, “We can open up new possibilities for identifying biomarker signatures in the spatial context of the tissue.”
Alimentiv, AcelaBio and PharmaNest’s collaboration will facilitate the seamless integration of robust digital pathology workflows and artificial intelligence into MASH clinical trials, ultimately leading to the development of personalized therapies and improving patient outcomes.
“Alimentiv is committed to scientific excellence and committed to developing innovative designs for early clinical trials and outcome assessments. Our expertise in endpoint assessments and precision medicine analysis, including bioinformatics and AI-powered digital pathology biomarker quantification, together with our collaborators, enables us to innovate and revolutionize the world of MASH clinical trials,” said Dr. Wendy Teft , VP of Precision Medicine at Alimentiv: “By integrating our respective technologies and expertise, we aim to equip clinical trial sponsors with the tools necessary to improve the quality of histological endpoints, discover new biomarkers and shorten drug development times “by gaining comprehensive insights into the underlying mechanisms of action of targeted MASH therapies.”
PharmaNest, known for its excellence in digital MASH pathology and artificial intelligence analysis, will play a critical role in this collaboration by providing high-resolution quantitative image analysis for individual fibers and cells as well as AI-powered biomarkers from the same Provides images to be reviewed by pathologists for critical endpoint assessments. Together, these organizations will improve the quality of current histologic endpoints required for interim FDA approval of MASH therapies and enable analysis of complex data sets, enabling a comprehensive understanding of MASH pathology and the discovery of new biomarkers.
“With our digital pathology platform, FibroNest, automated, high-resolution quantification of the fibrosis grade phenotype and associated tissue damage from the same pathologist-reviewed slides provides a robust and scalable method for generating continuous assessments that reveal subtle changes in fibrosis grade and disease activity and in MASH- Studies can be used to assist pathologists and improve the quantification of the effect of an intervention. Ph-FCS, our biomarker for digital fibrosis pathology, is an excellent diagnostic tool for early and severe fibrosis. Recently published results show that it can also predict liver-related events and outcomes, paving the way for its future qualification as a likely surrogate endpoint in MASH trials,” said Dr. Mathieu Petitjean, CEO of PharmaNest. ” The partnership with Alimentiv and AcelaBio ensures that sponsors receive an excellent end-to-end digital pathology tissue assay where preanalytical conditions are well controlled throughout the study period.
The collaboration between Alimentiv, AcelaBio and PharmaNest represents a significant advance in the integration of precision medicine and digital pathology solutions for MASH clinical trials. By combining their expertise, these companies aim to further increase the efficiency of early drug development to provide patients with safe and effective therapies more quickly to be able to provide.
Clinical trial sponsors interested in the benefits of this collaboration are encouraged to contact the respective companies for further information.
SOURCE: PRNewswire
